FDA Clearance Tracker · P970042-S002
MEDSTONE STS LITHOTRIPTER
Last checked: Nov 20, 2026Latest source record: Aug 20, 2002 (this decision)Source: openFDAMethods & limitations
Decided
Aug 20, 2002
Approved
Time to decision
180 days
Received Feb 21, 2002. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P970042-S002
- Device name
- MEDSTONE STS LITHOTRIPTER
- Applicant
- Medstone Intl., Inc.
- Applicant location
- Aliso Viejo, CA
- Received
- Feb 21, 2002
- Decided
- Aug 20, 2002
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P970042
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR 1) THE USE OF TWO GENERIC URSODIOLS, ONE MANUFACTURED BY AMIDE PHARMACEUTICAL AND ONE BY TEVA PHARMACEUTICAL, IN ADDITION TO ACTIGALL; 2) A CHANGE IN THE POST-APPROVAL STUDY'S MEDICAL MONITOR TO JOAN L. DRUCKER M.D., R.S.I.; AND 3) SEVERAL MINOR CLARIFICATIONS, CORRECTIONS AND EDITORIAL CHANGES TO THE POST-APPROVAL STUDY PROTOCOL. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE SAME TRADE NAME, MEDSTONE STS LITHOTRIPTER, AND IS INDICATED FOR THE TREATMENT OF SYMPTOMATIC, SOLITARY, RADIOLUCENT, NON-CALCIFIED GALLSTONES (BETWEEN 4 AND 20 MM IN MAXIMUM DIAMETER) IN ADULTS PATIENTS FOR WHOM SURGICAL REMOVAL OF THE GALLBLADDER IS MEDICALLY CONTRAINDICATED AND IN SYMPTOMATIC HIGH-RISK PATIENTS WHO HAVE ACTIVELY REFUSED SURGERY. COMBINATION THERAPY CONSISTS OF 1)ADMINISTRATION OF NOVARTIS PHARMACEUTICAL ACTIGALL, OR AMIDE PHARMACEUTICAL URSODIOL, OR TEVA PHARMACEUTICAL URSODIOL (8-10 MG/KG/DAY) FOR AT LEAST TWO WEEKS PRE-LITHOTRIPSY, 2) LITHOTRIPSY TREATMENTS OF UP TO 2000 24 KV SHOCKS, AND 3) CONTINUED ADMINISTRATION OF URSODIOL UNTIL A STONE-FREE STATE IS ACHIEVED.
Source documents
Other decisions for Medstone Intl., Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.